RxIndia
Loading clinical data...
Loading clinical data...
Authoritative Clinical Reference
| Parameter | Recommendation |
|
Starting dose
|
5–10 mg IV bolus |
|
Titration
|
Repeat 5–10 mg IV every 3–4 minutes as needed based on blood pressure response |
|
Usual maintenance dose
|
Titrated to blood pressure; cumulative dosing based on response |
|
Maximum dose
|
50 mg total per anaesthetic procedure |
| Parameter | Recommendation |
|
Starting dose
|
5–25 mg IV bolus |
|
Titration
|
Repeat as needed based on haemodynamic response |
|
Usual maintenance dose
|
Bolus dosing preferred; continuous infusion rarely used |
|
Maximum dose
|
Titrate to effect; no defined upper limit |
|
Duration
|
Short-term use during acute hypotensive episodes |
| Parameter | Recommendation |
|
Starting dose
|
25 mg oral 2–3 times daily |
|
Titration
|
May increase to 50 mg 2–3 times daily based on response |
|
Usual maintenance dose
|
25–50 mg oral 2–3 times daily |
|
Maximum dose
|
150 mg/day |
| Parameter | Recommendation |
|
Starting dose (IV bolus)
|
0.1–0.2 mg/kg/dose |
|
Titration
|
Repeat every 5–10 minutes based on blood pressure and heart rate response |
|
Usual maintenance dose
|
Based on haemodynamic response; bolus dosing preferred |
|
Maximum dose
|
10 mg per single dose |
|
Minimum age
|
No fixed lower age limit; use only under paediatric anaesthetist or intensivist supervision |
| Renal Function | Recommendation |
| Mild to moderate impairment | No specific dose adjustment required |
| Severe impairment | Use with caution; reduced clearance may lead to drug accumulation |
| Severity | Recommendation |
| Mild impairment | No dose adjustment required; use with caution |
| Moderate impairment | Use with caution; no specific dose adjustment |
| Severe impairment | Use with caution; hepatic metabolism may be impaired; monitor for prolonged duration of effect |
| Consideration | Recommendation |
| Overall safety | Generally considered safe for short-term intraoperative use |
| When it may be used | Preferred agent for spinal/epidural anaesthesia-induced hypotension in obstetrics, particularly when maternal heart rate is low or borderline |
| Preferred alternatives | Phenylephrine may be preferred when heart rate is normal or elevated |
| Monitoring | Maternal heart rate, blood pressure; fetal heart rate monitoring |
| Consideration | Recommendation |
| Compatibility | Likely compatible with breastfeeding at perioperative doses |
| Drug levels in milk | No significant transfer expected with short-term perioperative use |
| Preferred alternatives | Oral/chronic use discouraged during lactation |
| Infant monitoring | Restlessness, poor feeding, irritability, weight gain if repeated maternal use |
| Consideration | Recommendation |
| Starting dose | Lower end of dose range (5 mg IV bolus) |
| Titration | Slower titration preferred |
| Risks | Hypertension, tachyarrhythmias, agitation, urinary retention, CNS stimulation |
| Monitoring | Blood pressure, heart rate, cardiac rhythm, urinary output |
| Interacting Drug | Effect / Mechanism | Recommendation |
| Monoamine oxidase inhibitors (MAOIs) | Risk of hypertensive crisis due to inhibited catecholamine breakdown |
Contraindicated — avoid combination
|
| Ergot alkaloids | Additive vasoconstriction; risk of severe peripheral ischaemia |
Avoid combination
|
| Other sympathomimetics (pseudoephedrine, phenylephrine, adrenaline) | Additive cardiovascular toxicity |
Avoid or use with extreme caution
|
| Tricyclic antidepressants | Potentiation of pressor effect |
Avoid or monitor closely
|
| Interacting Drug | Effect / Mechanism | Recommendation |
| Beta-blockers | May reduce efficacy of ephedrine; paradoxical hypertension possible | Monitor blood pressure closely |
| Halothane and other halogenated anaesthetics | Sensitization of myocardium to catecholamine-induced arrhythmias | Avoid high doses of ephedrine |
| Antihypertensives | May blunt hypotensive effect of antihypertensives | May require dose adjustment of antihypertensives |
| Digoxin | Additive risk of arrhythmias | Monitor cardiac rhythm |
| Theophylline | Additive CNS and cardiovascular stimulation | Monitor for toxicity signs |
| Adverse Effect | Clinical Note |
| Arrhythmias (atrial or ventricular) | May require immediate discontinuation |
| Hypertensive crisis | Requires immediate management |
| Pulmonary oedema | Rare; may occur with overdose |
| Myocardial ischaemia | Monitor for chest pain in at-risk patients |
| CNS overstimulation or seizures | At high doses or with rapid IV bolus; requires hospitalisation |
| Phase | Parameters |
|
Baseline
|
Blood pressure, heart rate, ECG |
|
During treatment
|
Continuous BP and HR monitoring during IV administration |
|
Long-term
|
Not applicable — ephedrine is not intended for long-term use |
This platform is designed strictly for healthcare professionals. Data provided is synthesized from authoritative pharmacological sources and clinical registries. Do not use for consumer medical decisions. Always verify critical dosing and contraindications with official institutional protocols and peer-reviewed journals.
Help us improve our clinical database for the medical community.